Abstract
Cofactor engineering is a common strategy to improve amino acid production. 4-hydroxyisoleucine (4-HIL), a nonproteinogenic amino acid, exhibits unique insulinotropic and insulin-sensitizing activities, therefore has potential medical value in treating diabetes. In our previous study, l-isoleucine (Ile) dioxygenase gene ido was overexpressed in an Ile-producing Corynebacterium glutamicum strain, and 4-HIL was de novo synthesized from glucose. In this study, to increase the NADPH supply, the endogenous NAD+ kinase gene ppnK and glucose-6-phosphate dehydrogenase gene zwf were co-expressed with ido. The resulting strain SL01 produced 81.12 ± 5.96 mM 4-HIL, 62% higher than the ido-mere expressing strain SN02. However, the strain SL02 co-expressing exogenous NADH kinase gene POS5 with ido grew slowly and its 4-HIL production decreased by 12%, perhaps due to the lower 2-oxoglutarate (OG) level and slightly weaker membrane permeability. To increase OG availability for 4-HIL conversion, the serine/threonine protein kinase G gene pknG was deleted and replaced by ido gene in SL02. The growth of the resulting strain SL04 was restored and 4-HIL production was improved to 84.14 ± 6.38 mM; meanwhile, the conversion ratio of Ile to 4-HIL reached up to 0.98 ± 0.01 mol/mol. Therefore, sufficient NADPH supply and OG availability may be benefit to 4-HIL de novo biosynthesis in recombinant C. glutamicum.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.